- Organizations: Neurotech Pharmaceuticals
Business
Alcon acquires Neurotech, MacTel therapy Encelto
Clocking in at $550 million, the deal expands the company’s retinal portfolio with the first and only treatment for MacTel.
Products
CMS assigns permanent J-code for Neurotech's ENCELTO cell therapy
The allogeneic encapsulated cell-based therapy is the first and only treatment approved by the FDA for the treatment of MacTel.
Products
Clinicians perform first FDA-approved ENCELTO treatment for MacTel
As the first-ever FDA-approved MacTel therapy, ENCELTO (revakinagene taroretcel-lwey) is a single-dose ocular implant administered via an outpatient vitreoretinal surgery.
Business
BVI Medical and Neurotech name new CCOs
With over 20 years of executive leadership experience each, Andrew Chang and Beth Marsh will lead commercialization efforts for their respective companies’ upcoming product launches.
Products
FDA approves Neurotech's ENCELTO cell therapy for MacTel
Approval of revakinagene taroretcel-lwey is the first-ever for the treatment of this rare, neurodegenerative retinal disease.
Pipeline
FDA extends Neurotech's BLA PDUFA date for MacTel therapy
Review period of NT-501, an encapsulated cell therapy, now has a target date of March 2025.
Events
KOLs eye the future of genetic engineering and cell transplantation
Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.
Pipeline